Trial Profile
Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
- Indications Cancer metastases; Liver metastases; Uveal melanoma
- Focus Therapeutic Use
- 02 Dec 2023 Results comparing overall survival on tebentafusp or pembrolizumab (IMCgp100-202) to nivolumab plus ipilimumab (GEM1402) in untreated mUM using propensity scoring methods, published in the Annals of Oncology.
- 13 Sep 2022 Using individual patient data from two studies (NCT03070392 & NCT02626962) a propensity score (PS) weighted analysis was done to compare overall survival of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma, presented at the 47th European Society for Medical Oncology Congress.
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.